Quick Answer
EXOZYMES INC. reported Cash and Equivalents of $3.04 million for fiscal year 2025.
EXOZYMES INC. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $3.04M | -68.7% |
| 2024 | $9.72M | +14508.3% |
| 2023 | $66.5K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $5.10M | +2079.5% | -27.0% |
| June 30, 2025 | $6.99M | — | -17.9% |
| March 31, 2025 | $8.51M | — | -12.4% |
| December 31, 2024 | $9.72M | +14508.3% | +4054.7% |
| September 30, 2024 | $233.9K | — | +251.6% |
| December 31, 2023 | $66.5K | — | — |
- EXOZYMES INC. showed a decrease of -68.7% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2023–2025 period, EXOZYMES INC.’s cash and equivalents has grown by 4468.2% (from $66.5 thousand to $3.04 million).
- The most recent figure is from EXOZYMES INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: